Rho-associated protein kinase 2 (ROCK2) (ROCK2)

Rho-associated protein kinase 2 (ROCK2) is a serine/threonine kinase that serves as a major downstream effector of the small GTPase RhoA. It is a critical regulator of the actin cytoskeleton, influencing cellular processes such as contraction, motility, morphology, and polarity [1, 6, 10]. ROCK2 functions by phosphorylating a variety of substrates, including myosin light chain phosphatase (MYPT1) and LIM kinases, which in turn regulate actomyosin contractility and actin filament stabilization [6, 7, 10]. Beyond its role in cytoskeletal dynamics, ROCK2 is involved in cell cycle progression, apoptosis, and gene expression [7, 9, 13]. Dysregulation of ROCK2 signaling is implicated in the pathogenesis of several diseases, including cardiovascular disorders like hypertension and heart failure, fibrotic diseases, and various cancers where it promotes tumor invasion and metastasis [8, 11, 12, 15]. Therapeutic targeting of ROCK2 has led to the development of inhibitors like Belumosudil, which is used to treat chronic graft-versus-host disease, and non-selective inhibitors like Fasudil for vascular conditions [13, 14, 18]. However, systemic use of ROCK inhibitors can be limited by safety concerns such as hypotension due to their potent vasodilatory effects [11, 12].

Other names

Rho-associated, coiled-coil-containing protein kinase 2Rho-associated, coiled-coil-containing protein kinase IIROCK-IIp164 ROCK-2Rho kinase 2

Competitive inhibition of ATP binding to the kinase domain [12, 14], preventing the phosphorylation of downstream substrates such as myosin light chain phosphatase (MYPT1) and myosin light chain (MLC) [6, 7, 10, 12, 14, 15], thereby modulating actomyosin contractility and cytoskeletal dynamics [12, 13].